Most Read Articles
01 Apr 2013
Aspergillus colonization may lead to an increase in the risk of bronchiolitis obliterans syndrome. This study determined the impact of colonization of conidia Aspergillus species after post lung transplantation.
16 Jan 2018
No standard currently exists for the growing number of patients with multidrug-resistant strains of Helicobacter pylori, but a recent study has shown the safety and reliability of a 12-day low-dose rifabutin/high-dose proton pump inhibitor (PPI) regimen in patients infected with triple-resistant strains.
Roshini Claire Anthony, 10 Jan 2018

Adding rifampicin to standard antibiotic therapy does not improve outcomes in individuals with Staphylococcus aureus (S. aureus) bacteraemia, the ARREST* trial shows. However, rifampicin may contribute towards a minor reduction in bacteraemia recurrence.

14 Jan 2018
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.

Self-administered isoniazid, rifapentine noninferior to directly observed treatment of latent TB infection

10 Nov 2017

Self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis infection is feasible in the United States, and this treatment can be used in similar settings when direct observation is not viable, suggests a new study.

A total of 1,002 adults (median age 36 years; 48 percent women; 77 percent enrolled at the US sites) from outpatient tuberculosis clinics in the US, Spain, Hong Kong and South Africa received once-weekly isoniazid and rifapentine by direct observation, self-administration with monthly monitoring, or self-administration with weekly text message reminders and monthly monitoring.

Treatment completion, defined as 11 or more doses within 16 weeks and measured using clinical documentation and pill counts for direct observation, and self-reports, pill counts and medication event-monitoring devices for self-administration, was the primary outcome. The secondary outcomes were adverse events.

Treatment completion was highest in the direct-observation group at 87.2 percent (95 percent CI, 83.1 to 90.5 percent), followed by 76.4 percent (71.3 to 80.8 percent) in the self-administration‒with‒reminders group and 74.0 percent (68.9 to 78.6 percent) in the self-administration group.

In the US, treatment completion was 85.4 (80.4 to 89.4), 76.7 (70.9 to 81.7 percent) and 77.9 (72.7 to 82.6 percent), respectively. Self-administered therapy without reminders was noninferior to direct observation in the US, and no other comparisons met the noninferiority criteria.

There were a few and similar drug-related adverse events across all groups.

“Expanding latent tuberculosis treatment is important to decrease active disease globally. Once-weekly isoniazid and rifapentine for 12 doses is effective but limited by requiring direct observation,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Apr 2013
Aspergillus colonization may lead to an increase in the risk of bronchiolitis obliterans syndrome. This study determined the impact of colonization of conidia Aspergillus species after post lung transplantation.
16 Jan 2018
No standard currently exists for the growing number of patients with multidrug-resistant strains of Helicobacter pylori, but a recent study has shown the safety and reliability of a 12-day low-dose rifabutin/high-dose proton pump inhibitor (PPI) regimen in patients infected with triple-resistant strains.
Roshini Claire Anthony, 10 Jan 2018

Adding rifampicin to standard antibiotic therapy does not improve outcomes in individuals with Staphylococcus aureus (S. aureus) bacteraemia, the ARREST* trial shows. However, rifampicin may contribute towards a minor reduction in bacteraemia recurrence.

14 Jan 2018
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.